At the satellite clinic in Mighoma, Tchibanga, nurse Merleye Nongou adjusts an IV while data clerk Naomie Badinga records patient details and Dr. Alex Hounmenou Zinsou oversees care—part of a quiet but groundbreaking trial that could reshape how malaria is treated across Africa. The patient is receiving SPAP, a single-dose combination therapy developed by researchers at the German Center for Infection Research (DZIF), which marries four existing antimalarial drugs—sulfadoxine, pyrimethamine, artesunate, and pyronaridine—into one powerful treatment. With malaria still claiming over 600,000 lives annually, mostly children under five in sub-Saharan Africa, SPAP offers a lifeline: a treatment that’s not only simpler to administer but also designed to outsmart the parasite’s growing resistance to current drugs.
For decades, standard malaria therapy has required patients to take medication over three days—a hurdle in remote areas where access to healthcare is limited and follow-up visits are rare. Missed doses fuel drug resistance, undermining years of progress. SPAP sidesteps this by delivering a full course in one dose, increasing the likelihood of complete treatment and reducing the chance of resistance emerging. Early clinical trials in Gabon, led by Prof. Ghyslain Mombo-Ngoma—recently named to the 2026 TIME100 Health list—showed strong efficacy and safety, findings now published in Malaria Journal.
The success has paved the way for a pan-African clinical trial, set to launch across multiple countries, to test SPAP under real-world conditions. The World Health Organization has already recognized its potential, placing SPAP on its list of priority malaria medicines under development. Fixed-dose tablets for the trial are expected to begin production this year. If results hold, SPAP could become a cornerstone of malaria treatment across the continent.
“This study addresses one of the most pressing challenges in malaria treatment: maintaining effectiveness while reducing the risk of resistance development,” says Mombo-Ngoma, who leads research at both the Bernhard Nocht Institute for Tropical Medicine (BNITM) and Gabon’s Centre de Recherches Médicales de Lambaréné (CERMEL). The project unites African and European scientists, including co-leads Prof. Peter Kremsner of Tübingen and Dr. Oumou Maïga Ascofaré of BNITM and Ghana’s Kumasi Centre for Collaborative Research, reflecting a model of equitable, collaborative science that centers African institutions.
With over 200 million malaria cases globally each year, the need for faster, more reliable treatments has never been greater. SPAP doesn’t just offer a medical breakthrough—it promises a practical one. A single pill, taken once, could mean fewer hospital visits, lower costs, and more lives saved. As the pan-African trial prepares to roll out, the world watches a quiet revolution in global health, born in Mighoma and built for the future.